Juniper Pharma Services strengthens capsule capability with Xcelodose

2 years ago

Nottingham, UK – Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), has reinforced its early stage capsule filling expertise with the expansion of its Xcelodose® powder micro-dosing system as part of its suite of GMP capabilities. The move by the contract development and manufacturing organisation (CDMO) follows demand from its clients to

Demonstrating Therapeutic Equivalence for Generic Topical Products

2 years ago

Our Chief Technical Officer, Rob Harris discusses how the determination of topical bioequivalence requires a multi-faceted approach, tailored specifically to the generic-drug formulation in this article as featured in Pharmaceutical Technology entitled ‘Demonstrating Therapeutic Equivalence for Generic Topical Products’. You can read full article online via PharmTech.com.

Delegates are shown around the lab at Juniper Pharma Services

2 years ago

Businesses from one of China’s biggest international trading cities have held talks with life sciences and healthcare firms from Nottingham during a tour of the city. The delegation from Ningbo – the fifth-biggest container port in the world – has been exploring commercial links with Nottingham as part of a wider push to grow trade

Juniper appointed partner for groundbreaking cancer drug delivery platform

3 years ago

Nottingham, UK – Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP), has entered into a long-term collaboration with OxSonics Limited (“OxSonics”) to support the development, scale-up, and GMP manufacturing of OxSonics’ proprietary “sono-sensitive particles.” The collaboration will see the contract development and manufacturing organisation (CDMO) support the Oxford-based company develop these injectable particles, which when used in conjunction

Juniper Pharma Services obtains Specials licence

3 years ago

Nottingham, UK – Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, Inc. (Nasdaq: JNP) has been granted permission by the Medicines and Healthcare products Regulatory Agency (MHRA) to manufacture and supply bulk unlicensed medicines. This licence from the UK’s regulatory body allows the contract development and manufacturing organisation (CDMO) to produce tablets, capsules and other

Molecular Profiles is now Juniper Pharma Services

3 years ago

Nottingham, UK – April 13, 2015 – Molecular Profiles has announced that the company is to adopt Juniper Pharma Services as its new brand name from April 13th 2015. The move has coincided with its Boston-based parent company Columbia Laboratories, Inc. adopting its new brand identity as Juniper Pharmaceuticals, Inc., effective Monday, April 13, 2015,

Columbia Laboratories Acquires Exclusive Worldwide License to a Novel Segmented Intra-vaginal Ring Delivery Technology

3 years ago

BOSTON, Mar. 30, 2015  — Columbia Laboratories, Inc. (Nasdaq: CBRX), a specialty pharmaceutical company focused on the development of therapeutics for women’s health, has licensed exclusive worldwide rights to a novel intra-vaginal ring (“IVR”) technology for the delivery of one or more pharmaceuticals at different dosages and release rates in a single segmented ring. This